On 10/15/25, Editas Medicine Inc (NASDAQ: EDIT) stock enjoyed a major increase of 13.1%, closing at $4.06. Moreover, exceptionally high trading volume at 202% of normal accompanied the advance. The stock has risen 3.3% during the last week and has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Editas Medicine has a current Value Trend Rating of C (Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Editas Medicine has a very low Appreciation Score of 10 but a very high Power Rating of 92, producing the Neutral Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment